Abstract
Multiple experimental approaches have been employed to study exocrine pancreatic cancer, including the use of animals as surrogates for the human disease. Animals have the advantage that they can be manipulated to address specific hypotheses regarding mechanisms underlying this disease. Implicit in this opportunity is the necessity to match the question being asked with an appropriate animal model. Several approaches to modeling pancreatic cancer have been established that involve animals. First, xenogeneic cell transplantation, generally into immunocompromised rodent subcutis or pancreas, allows examination of (1) the effect of host environment on human or rodent pancreatic cancer cells, (2) whether specific genetic changes in donor cells correlate with certain cancer cell behaviors, and (3) novel approaches to cancer therapy or imaging of tumor growth. Second, carcinogen administration, typically to hamster or rat, allows examination of whether specific genetic, biochemical, cellular, and tissue phenotypic changes, including progression to neoplasia, accompany exposure to a particular chemical. Third, genetically engineered animals, usually transgenic or gene targeted mice, allow examination of (1) whether genetic changes, including oncogene overexpression/mutation or tumor suppressor gene loss, can increase the risk for neoplastic progression, (2) whether specific genetic changes can cooperate during pancreatic carcinogenesis, and (3) how the genetic signature of a neoplasm correlates with particular biological aspects of tumor initiation and progression. Collectively, these experimental approaches permit detailed exploration of pancreatic cancer genetics and biology in the whole animal context, thereby mimicking the environment in which human disease occurs.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Sohn, T. A. (2002) The molecular genetics of pancreatic ductal carcinoma. Minerva Chir. 57, 561ā574.
Parker, S., Tong, T., Bolden, S., et. al. (1996) Cancer Statistics. CA J. Clin. 65, 5ā27.
Sakorafas, G. H. and Tsiotou, A. G. (1999) Multi-step pancreatic carcinogenesis and its clinical implications. Eur. J. Surg. Oncol. 25, 562ā565.
Hilgers, W. and Kern, S. E. (1999) Molecular genetic basis of pancreatic adenocarcinoma. Genes Chromosom. Cancer 26, 1ā12.
Caldas, C. and Kern, S. E. (1995) K-ras mutation and pancreatic adenocarcinoma. Int. J. Pancreatol. 18, 1ā6.
Gunji, N., Oda, T., Todoroki, T., et al. (1998) Pancreatic carcinoma: Correlation between E-cadherin and alpha-catenin expression status and liver metastasis. Cancer 82, 1649ā1656.
Visser, C. J., Bruggink, A. H., Korc, M., et al. (1996) Overexpression of transforming growth factor-alpha and epidermal growth factor receptor, but not epidermal growth factor, in exocrine pancreatic tumours in hamsters. Carcinogenesis 17, 779ā785.
Hruban, R. H. W. and Kern, S. E. (2000) Genetic progression in the pancreatic ducts. Am. J. Pathol. 156, 1821ā1825.
Mangray, S. and King, T. C. (1998) Molecular pathobiology of pancreatic adenocarcinoma. Front. Biosci. 3, D1148ā1160.
Perugini, R. A., McDade, T. P., Vittimberga, F. J. Jr., and Callery, M. P. (1998) The molecular and cellular biology of pancreatic cancer. Crit. Rev. Eukaryot. Gene Express. 8, 377ā393.
Goggins, M., Kern, S. E., Offerhaus, J. A., and Hruban, R. H. (1999) Progress in cancer genetics: Lessons from pancreatic cancer. Ann. Oncol. 10, 4ā8.
Kumar, V., Bustin, S. A., and McKay, I. A. (1995) Transforming growth factor alpha. Cell Biol. Int. 19, 373ā388.
Sakorafas, G. H., Tsiotou, A. G., and Tsiotos, G. G. (2000) Molecular biology of pancreatic cancer; oncogenes, tumour suppressor genes, growth factors, and their receptors from a clinical perspective. Cancer Treat. Rev. 26, 29ā52.
Moore, P. S., Sipos, B., Orlandini, S., et al. (2001) Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Virchows Arch. 439, 798ā802.
Aoki, K., Yoshida, T., Matsumoto, N., Ide, H., Sugimura, T., and Terada, M. (1997) Suppression of Ki-ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with Ki-ras mutation but not those without Ki-ras mutation. Mol. Carcinog. 20, 251ā258.
Kita, K., Saito, S., Morioka, C. Y., and Watanabe, A. (1999) Growth inhibition of human pancreatic cancer cell lines by anti-sense oligonucleotides specific to mutated K-ras genes. Int. J. Cancer 80, 553ā558.
Hahn, S. A., Seymour, A. B., Hoque, A. T., et al. (1995) Allelotype of pancreatic adenocarcinoma using xenograft enrichment. Cancer Res. 55, 4670ā4675.
Capella, G., Farre, L., Villanueva, A., et al. (1999) Orthotopic models of human pancreatic cancer. Ann. NY Acad. Sci. 880, 103ā109.
Schwarz, R. E., McCarty, T. M., Peralta, E. A., Diamond, D. J., and Ellenhorn, J. D. (1999) An orthotopic in vivo model of human pancreatic cancer. Surgery 126, 562ā567.
Gingell, R., Wallcave, L., Nagel, D., Kupper, R., and Pour, P. (1976) Metabolism of the pancreatic carcinogens N-nitroso-bis-(2-oxopropyl)amine and N-nitroso-bis (2-hydroxypropyl)amine in the Syrian hamster. J. Natl. Cancer Inst. 57, 1175ā1178.
Pour, P. and Althoff, J. (1977) The effect of N-nitrosobis(2-oxopropyl)amine after oral administration to hamsters. Cancer Lett. 2, 323ā326.
Konishi, Y., Tsutsumi, M., and Tsujiuchi, T. (1998) Mechanistic analysis of pancreatic ductal carcinogenesis in hamsters. Pancreas 16, 300ā306.
Flaks, B., Moore, M. A., and Flaks, A. (1982) Ultrastructural analysis of pancreatic carcinogenesis. V. Changes in differentiation of acinar cells during chronic treatment with N-nitrosobis(2-hydroxypropyl)amine. Carcinogenesis 3, 485ā498.
Feng, Z., Hu, W., Chen, J. X., et al. (2002) Preferential DNA damage and poor repair determine ras gene mutational hotspot in human cancer. J. Natl. Cancer Inst. 94, 1527ā1536.
Okita, S., Tsutsumi, M., Onji, M., and Konishi, Y. (1995) p53 mutation without allelic loss and absence of mdm-2 amplification in a transplantable hamster pancreatic ductal adenocarcinoma and derived cell lines but not primary ductal adenocarcinomas in hamsters. Mol. Carcinog. 13, 266ā271.
Erill, N., Cuatrecasas, M., Sancho, F. J., et al. (1996) K-ras and p53 mutations in hamster pancreatic ductal adenocarcinomas and cell lines. Am. J. Pathol. 149, 1333ā1339.
Flaks, B., Moore, M. A., and Flaks, A. (1981) Ultrastructural analysis of pancreatic carcinogenesis. IV. Pseudoductular transformation of acini in the hamster pancreas during N-nitroso-bis(2-hydroxypropyl)amine carcinogenesis. Carcinogenesis 2, 1241ā1253.
Flaks, B., Moore, M. A., and Flaks, A. (1982) Ultrastructural analysis of pancreatic carcinogenesis. VI. Early changes in hamster acinar cells induced by N-nitroso-bis(2-hydroxypropyl)amine. Carcinogenesis 3, 1063ā1070.
Hall, P. A. and Lemoine, N. R. (1993) Models of pancreatic cancer. Cancer Surv. 16, 135ā155.
Rivera, J. A., Graeme-Cook, F., Werner, J., et al. (1997) A rat model of pancreatic ductal adenocarcinoma: Targeting chemical carcinogens. Surgery 122, 82ā90.
Rao, M. S. (1987) Animal models of exocrine pancreatic carcinogenesis. Cancer Metastas. Rev. 6, 665ā676.
Pour, P. M., Weide, L., Liu, G., et al. (1997) Experimental evidence for the origin of ductal-type adenocarcinoma from the islets of Langerhans. Am. J. Pathol. 150, 2167ā2180.
Schaeffer, B. K., Zurlo, J., and Longnecker, D. S. (1990) Activation of c-Ki-ras not detectable in adenomas or adenocarcinomas arising in rat pancreas. Mol. Carcinog. 3, 165ā170.
Dissin, J., Mills, L. R., Mains, D. L., Black, O. Jr., and Webster, P. D. (1975) Experimental induction of pancreatic adenocarcinoma in rats. J. Natl. Cancer Inst. 55, 857ā864.
Bockman, D. E., Black, O. Jr., Mills, L. R., Mainz, D. L., and Webster, P. D. (1976) Fine structure of pancreatic adenocarcinoma induced in rats by 7,12-dimethyl-benz(a)anthracene. J. Natl. Cancer Inst. 57, 931ā936.
Albanese, C., Hulit, J., Sakamaki, T., and Pestell, R. G. (2002) Recent advances in inducible expression in transgenic mice. Semin. Cell Dev. Biol. 13, 129ā141.
Tuveson, D. A. and Jacks, T. (2002) Technologically advanced cancer modeling in mice. Curr. Opin. Genet. Dev. 12, 105ā110.
Yamamoto, A., Hen, R., and Dauer, W. T. (2001) The ons and offs of inducible transgenic technology: A review. Neurobiol. Dis. 8, 923ā932.
Grippo, P. J., Nowlin, P. S., Cassaday, R. D., and Sandgren, E. P. (2002) Cell-specific transgene expression from a widely transcribed promoter using Cre/lox in mice. Genesis 32, 277ā286.
Lewandoski, M. (2001) Conditional control of gene expression in the mouse. Nat. Rev. Genet. 2, 743ā755.
Sauer, B. (1998) Inducible gene targeting in mice using the Cre/lox system. Methods 14, 381ā392.
Hammer, R. E., Swift, G. H., Ornitz, D. M., et al. (1987) The rat elastase I regulatory element is an enhancer that directs correct cell specificity and developmental onset of expression in transgenic mice. Mol. Cell Biol. 7, 2956ā2967.
Ornitz, D. M., Palmiter, R. D., Hammer, R. E., et al. (1985) Specific expression of an elastase-human growth hormone fusion gene in pancreatic acinar cells of transgenic mice. Nature 313, 600ā602.
De Lisle, R. C. and Logsdon, C. D. (1990) Pancreatic acinar cells in culture: Expression of acinar and ductal antigens in a growth-related manner. Eur. J. Cell Biol. 51, 64ā75.
Yuan, S., Duguid, W. P., Agapitos, D., Wyllie, B., and Rosenberg, L. (1997) Phenotypic modulation of hamster acinar cells by culture in collagen matrix. Exp. Cell Res. 237, 247ā258.
Arias, A. E. and Bendayan, M. (1993) Differentiation of pancreatic acinar cells into duct-like cells in vitro. Lab. Invest. 69, 518ā530.
Hall, P. A. and Lemoine, N. R. (1992) Rapid acinar to ductal transdifferentiation in cultured human exocrine pancreas. J. Pathol. 166, 97ā103.
Vila, M. R., Lloreta, J., and Real, F. X. (1994) Normal human pancreas cultures display functional ductal characteristics. Lab. Invest. 71, 423ā431.
Wagner, M., Luhrs, H., Kloppel, G., Adler, G., and Schmid, R. M. (1998) Malignant transformation of duct-like cells originating from acini in transforming growth factor transgenic mice. Gastroenterology 115, 1254ā1262.
Quaife, C. J., Pinkert, C. A., Ornitz, D. M., Palmiter, R. D., and Brinster, R. L. (1987) Pancreatic neoplasia induced by ras expression in acinar cells of transgenic mice. Cell 48, 1023ā1034.
Ornitz, D. M., Hammer, R. E., Messing, A., Palmiter, R. D., and Brinster, R. L. (1987) Pancreatic neoplasia induced by SV40 T-antigen expression in acinar cells of transgenic mice. Science 238, 188ā193.
Sandgren, E. P., Luetteke, N. C., Palmiter, R. D., Brinster, R. L., and Lee, D. C. (1990) Overexpression of TGF alpha in transgenic mice: Induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast. Cell 61, 1121ā1135.
Sandgren, E. P., Quaife, C. J., Paulovich, A. G., Palmiter, R. D., and Brinster, R. L. (1991) Pancreatic tumor pathogenesis reflects the causative genetic lesion. Proc. Natl. Acad. Sci. USA 88, 93ā97.
Grippo, P. J., Nowlin, P. S., Demeure, M. J., Longnecker, D. S., and Sandgren, E. P. (2003) Preinvasive pancreatic neoplasia of ductal phenotype induced by acinar cell targeting of mutant kras in transgenic mice. Cancer Res. 63, 2016ā2019.
Peat, N., Gendler, S. J., Lalani, N., Duhig, T., and Taylor-Papadimitriou, J. (1992) Tissue-specific expression of a human polymorphic epithelial mucin (MUC1) in transgenic mice. Cancer Res. 52, 1954ā1960.
Goetze, J. P., Nielsen, F. C., Burcharth, F., and Rehfeld, J. F. (2000) Closing the gastrin loop in pancreatic carcinoma: Coexpression of gastrin and its receptor in solid human pancreatic adenocarcinoma. Cancer 88, 2487ā2494.
Watson, S. A. and Caplin, M. (2002) Correspondence re: Weinberg et al., Cholecystokinin and gastrin levels are not elevated in pancreatic carcinoma. Cancer Epidemiol. Biomark. Prev. 10, 721ā722. Cancer Epidemiol. Biomark. Prev. 11, 219.
Weinberg, D. S., Heyt, G J., Cavanagh, M., Pitchon, D., McGlynn, K. A., and London, W. T. (2001) Cholecystokinin and gastrin levels are not elevated in human pancreatic adenocarcinoma. Cancer Epidemiol. Biomark. Prev. 10, 721ā722.
Mukherjee, P., Ginardi, A. R., Madsen, C. S., et al. (2000) Mice with spontaneous pancreatic cancer naturally develop MUC-1-specific CTLs that eradicate tumors when adoptively transferred. J. Immunol. 165, 3451ā3460.
Yen, T. W., Sandgren, E. P., Liggitt, H. D., et al. (2002) The gastrin receptor promotes pancreatic growth in transgenic mice. Pancreas 24, 121ā129.
Clerc, P., Leung-Theung-Long, S., Wang, T. C., et al. (2002) Expression of CCK2 receptors in the murine pancreas: Proliferation, transdifferentiation of acinar cells, and neoplasia. Gastroenterology 122, 428ā437.
Grippo, P. J. and Sandgren, E. P. (2000) Highly invasive transitional cell carcinoma of the bladder in a simian virus 40 T-antigen transgenic mouse model. Am. J. Pathol. 157, 805ā813.
Brembeck, F. H., Schreiber, F. S., Deramaudt, T. B., et al. (2003) The mutant K-ras oncogene causes pancreatic periductal lymphocytic infiltration and gastric mucous neck cell hyperplasia in transgenic mice. Cancer Res. 63, 2005ā2009.
Gu, G., Dubauskaite, J., and Melton, D. A. (2002) Direct evidence for the pancreatic lineage: NGN3+ cells are islet progenitors and are distinct from duct progenitors. Development 129, 2447ā2457.
Herrera, P. L., Nepote, V., and Delacour, A. (2002) Pancreatic cell lineage analyses in mice. Endocrine 19, 267ā278.
Song, S. Y., Gannon, M., Washington, M. K., et al. (1999) Expansion of Pdx1-expressing pancreatic epithelium and islet neogenesis in transgenic mice over-expressing transforming growth factor alpha. Gastroenterology 117, 1416ā1426.
Holland, A. M., Hale, M. A., Kagami, H., Hammer, R. E., and MacDonald, R. J. (2002) Experimental control of pancreatic development and maintenance. Proc. Natl. Acad. Sci. USA 99, 12236ā12241.
Donehower, L. A., Harvey, M., Slagle, B. L., et al. (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356, 215ā221.
Serrano, M., Lee, H., Chin, L., Cordon-Cardo, C., Beach, D., and DePinho, R. A. (1996) Role of the INK4a locus in tumor suppression and cell mortality. Cell 85, 27ā37.
Sirard, C., de la Pompa, J. L., Elia, A., et al. (1998) The tumor suppressor gene Smad4/Dpc4 is required for gastrulation and later for anterior development of the mouse embryo. Genes Dev. 12, 107ā119.
Sharpless, N. E., Alson, S., Chan, S., Silver, D. P., Castrillon, D. H., and DePinho, R. A. (2002) p16(INK4a) and p53 deficiency cooperate in tumorigenesis. Cancer Res. 62, 2761ā2765.
Yang, X., Li, C., Herrera, P. L., and Deng, C. X. (2002) Generation of Smad4/Dpc4 conditional knockout mice. Genesis 32, 80ā81.
Wagner, M., Greten, F. R., Weber, C. K., et al. (2001) A murine tumor progression model for pancreatic cancer recapitulating the genetic alterations of the human disease. Genes Dev. 15, 286ā293.
Bardeesy, N., Morgan, J., Sinha, M., et al. (2002) Obligate roles for p16(Ink4a) and p19(Arf)-p53 in the suppression of murine pancreatic neoplasia. Mol. Cell Biol. 22, 635ā643.
Cullingworth, J., Hooper, M. L., Harrison, D. J., et al. (2002) Carcinogen-induced pancreatic lesions in the mouse: Effect of Smad4 and Apc genotypes. Oncogene 21, 4696ā4701.
Takaku, K., Miyoshi, H., Matsunaga, A., Oshima, M., Sasaki, N., and Taketo, M. M. (1999) Gastric and duodenal polyps in Smad4 (Dpc4) knockout mice. Cancer Res. 59, 6113ā6117.
Morikane, K., Tempero, R., Sivinski, C. L., Kitajima, S., Gendler, S. J., and Hollingsworth, M. A. (2001) Influence of organ site and tumor cell type on MUC1-specific tumor immunity. Int. Immunol. 13, 233ā240.
Bouvet, M., Wang, J., Nardin, S. R., et al. (2002) Real-time optical imaging of primary tumor growth and multiple metastatic events in a pancreatic cancer orthotopic model. Cancer Res. 62, 1534ā1540.
Lee, N. C., Bouvet, M., Nardin, S., et al. (2000) Antimetastatic efficacy of adjuvant gemcitabine in a pancreatic cancer orthotopic model. Clin. Exp. Metastas. 18, 379ā384.
Alves, F., Contag, S., Missbach, M., et al. (2001) An orthotopic model of ductal adenocarcinoma of the pancreas in severe combined immunodeficient mice representing all steps of the metastatic cascade. Pancreas 23, 227ā235.
Tarbe, N., Evtimova, V., Burtscher, H., Jarsch, M., Alves, F., and Weidle, U. H. (2001) Transcriptional profiling of cell lines derived from an orthotopic pancreatic tumor model reveals metastasis-associated genes. Anticancer Res. 21, 3221ā3228.
Tsuzuki, Y., Mouta Carreira, C., Bockhorn, M., Xu, L., Jain, R. K., and Fukumura, D. (2001) Pancreas microenvironment promotes VEGF expression and tumor growth: Novel window models for pancreatic tumor angiogenesis and microcirculation. Lab. Invest. 81, 1439ā1451.
Bloomston, M., Shafii, A., Zervos, E. E., and Rosemurgy, A. S. (2002) TIMP-1 overexpression in pancreatic cancer attenuates tumor growth, decreases implantation and metastasis, and inhibits angiogenesis. J. Surg. Res. 102, 39ā44.
Wen, Y., Yan, D. H., Wang, B., et al. (2001) p202, an interferon-inducible protein, mediates multiple antitumor activities in human pancreatic cancer xenograft models. Cancer Res. 61, 7142ā7147.
Bruns, C. J., Harbison, M. T., Kuniyasu, H., Eue, I., and Fidler, I. J. (1999) In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. Neoplasia 1, 50ā62.
Solorzano, C. C., Baker, C. H., Tsan, R., et al. (2001) Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma. Clin. Cancer Res. 7, 2563ā2572.
Denham, D. W., Franz, M. G., Denham, W., et al. (1998) Directed antisense therapy confirms the role of protein kinase C-alpha in the tumorigenicity of pancreatic cancer. Surgery 124, 218ā223; discussion 223ā214.
Morioka, C. Y., Saito, S., Kita, K., and Watanabe, A. (2000) Curative resection of orthotopically implanted pancreatic cancer in Syrian golden hamsters. Int. J. Pancreatol. 28, 207ā213.
Juhl, H., Sievers, M., Baltzer, K., et al. (1995) A monoclonal antibody-cobra venom factor conjugate increases the tumor-specific uptake of a 99mTc-labeled anti-carcinoembryonic antigen antibody by a two-step approach. Cancer Res. 55, 5749sā5755s.
Matsushita, A., Onda, M., Uchida, E., Maekawa, R., and Yoshioka, T. (2001) Antitumor effect of a new selective matrix metalloproteinase inhibitor, MMI-166, on experimental pancreatic cancer. Int. J. Cancer 92, 434ā440.
Ng, S. S., Tsao, M. S., Nicklee, T., and Hedley, D. W. (2001) Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin. Cancer Res. 7, 3269ā3275.
Zervos, E. E., Shafii, A. E., and Rosemurgy, A. S. (1999) Matrix metalloproteinase (MMP) inhibition selectively decreases type II MMP activity in a murine model of pancreatic cancer. J. Surg. Res. 81, 65ā68.
Hotz, H. G., Hines, O. J., Hotz, B., Foitzik, T., Buhr, H. J., and Reber, H. A. (2003) Evaluation of vascular endothelial growth factor blockade and matrix metalloproteinase inhibition as a combination therapy for experimental human pancreatic cancer. J. Gastrointest. Surg. 7, 220ā227; discussion 227ā228.
Alves, F., Borchers, U., Padge, B., et al. (2001) Inhibitory effect of a matrix metalloproteinase inhibitor on growth and spread of human pancreatic ductal adenocarcinoma evaluated in an orthotopic severe combined immunodeficient (SCID) mouse model. Cancer Lett. 165, 161ā170.
Fu, X., Guadagni, F., and Hoffman, R. M. (1992) A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens. Proc. Natl. Acad. Sci. USA 89, 5645ā5649.
Farre, L., Casanova, I., Guerrero, S., Trias, M., Capella, G., and Mangues, R. (2002) Heterotopic implantation alters the regulation of apoptosis and the cell cycle and generates a new metastatic site in a human pancreatic tumor xenograft model. FASEB J. 16, 975ā982.
Liu, C. D., Tilch, L., Kwan, D., and McFadden, D. W. (2002) Vascular endothelial growth factor is increased in ascites from metastatic pancreatic cancer. J. Surg. Res. 102, 31ā34.
Morioka, C. Y., Saito, S., Ohzawa, K., and Watanabe, A. (2000) Homologous orthotopic implantation models of pancreatic ductal cancer in Syrian golden hamsters: Which is better for metastasis researchācell implantation or tissue implantation? Pancreas 20, 152ā157.
Hotz, H. G., Reber, H. A., Hotz, B., et al. (2001) An improved clinical model of orthotopic pancreatic cancer in immunocompetent Lewis rats. Pancreas 22, 113ā121.
He, Z., Evelhoch, J. L., Mohammad, R. M., et al. (2000) Magnetic resonance imaging to measure therapeutic response using an orthotopic model of human pancreatic cancer. Pancreas 21, 69ā76.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
Ā© 2005 Humana Press Inc.
About this protocol
Cite this protocol
Grippo, P.J., Sandgren, E.P. (2005). Modeling Pancreatic Cancer in Animals to Address Specific Hypotheses. In: Su, G.H. (eds) Pancreatic Cancer. Methods in Molecular Medicineā¢, vol 103. Humana Press. https://doi.org/10.1385/1-59259-780-7:217
Download citation
DOI: https://doi.org/10.1385/1-59259-780-7:217
Publisher Name: Humana Press
Print ISBN: 978-1-58829-107-3
Online ISBN: 978-1-59259-780-2
eBook Packages: Springer Protocols